spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  NHL 

 HSMN NewsFeed - 11 Dec 2025
NexGen Hyperbaric Expands National Presence to Florida, Adds New Professional Sports Customer, and Announces Flagship Facility Launch
Devices
 HSMN NewsFeed - 13 Jan 2025
Roche receives FDA clearance for new, highly-sensitive test to aid clinicians in diagnosing B-cell lymphoma
Diagnostics Oncology FDA
 HSMN NewsFeed - 28 Jun 2024
AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R)) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Sep 2023
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 May 2023
Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2023
Soligenix Provides Regulatory Update on HyBryte(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Feb 2023
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte(TM) New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2022
'Enhanced Lung Rest' with CytoSorb and ECMO Achieves High Survival in 100 Critically Ill COVID-19 Patients with Refractory Lung Failure from Five Major U.S. Hospitals
Devices
 HSMN NewsFeed - 31 Oct 2022
Actinium Announces Positive Top-line Results from Pivotal Phase 3 SIERRA Trial of Iomab-B in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2022
CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries
Devices Distribution
 HSMN NewsFeed - 2 May 2022
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany
Devices Group Purchasing
 HSMN NewsFeed - 28 Mar 2022
Avenge Bio Appoints Claudio Dansky Ullmann, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Jan 2022
CBMG Receives FDA Regenerative Medicine Advanced Therapy and Fast Track Designations for Bi-Specific Anti-CD19/CD20 CAR-T Cell Therapy for Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 20 Dec 2021
CytoSorbents Announces Publication of U.S. CTC Multicenter Registry Results Using CytoSorb(R) in Critically Ill COVID-19 Patients on Extracorporeal Membrane Oxygenation (ECMO)
Devices
 HSMN NewsFeed - 16 Dec 2021
Nordic Nanovector appoints Experienced International Life Sciences Executive Sandra Jonsson as Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 29 Nov 2021
Viracta Therapeutics Announces Orphan Drug Designation Granted by FDA for its All-Oral Combination of Nanatinostat and Valganciclovir (Nana-val) for the Treatment of Epstein Barr Virus-Positive Diffuse Large B-cell Lymphoma
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Nov 2021
Rigel Sharpens Focus on Its Advanced Portfolio Opportunities
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2021
Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 10 Sep 2021
CytoSorbents Announces Filing of an Investigational Device Exemption (IDE) for the U.S. Clinical Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR(TM) Antithrombotic Removal System During Urgent Cardiothoracic Surgery
Devices Surgery FDA
 HSMN NewsFeed - 13 Aug 2021
Rigel Pharmaceuticals Provides Update on COVID-19 Program
Biopharmaceuticals
 HSMN NewsFeed - 12 Aug 2021
Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR(TM) Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
Devices FDA
 HSMN NewsFeed - 14 May 2021
Rigel Appoints Alison L. Hannah, M.D. to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Apr 2021
Rinri Therapeutics Raises £10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss
Regenerative Medicine Venture Capital
 HSMN NewsFeed - 18 Jan 2021
Tessa Therapeutics Receives PRIME Designation from European Medicines Agency for CD30 CAR-T Therapy
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Jan 2021
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing
Devices Personnel
 HSMN NewsFeed - 23 Nov 2020
Rigel and Medison Announce Health Canada Approval of TAVALISSE(R), an Oral Medication for the Treatment of Adults with Chronic Immune Thrombocytopenia
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 9 Oct 2020
Innovent and Lilly Jointly Announce the NMPA Granted Marketing Approval for HALPRYZA(R) (Rituximab Injection) in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Jul 2020
CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development
Devices
 HSMN NewsFeed - 28 Jul 2020
CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data
Devices
 HSMN NewsFeed - 24 Jun 2020
CytoSorbents Announces Commercial Launch and Immediate Availability of CytoSorb To Treat Cytokine Storm In Many Latin American Countries As COVID-19 Cases Rise
Devices Product Launch
 HSMN NewsFeed - 28 May 2020
Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 May 2020
CytoSorb(R) is E.U. Approved to Remove Rivaroxaban, a Leading Factor Xa Inhibitor and Novel Oral Anticoagulant, During On-Pump Cardiothoracic Surgery
Devices Regulatory
 HSMN NewsFeed - 4 May 2020
CytoSorbents Promotes Vincent J. Capponi to President
Devices Personnel
 HSMN NewsFeed - 30 Apr 2020
Soligenix Announces Positive Phase 3 FLASH Study Demonstrates Increased Efficacy with Continued Treatment in Patients with Cutaneous T-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Apr 2020
Cytosorbents Appoints Dr. Efthymios N. Deliargyris, M.D., As Chief Medical Officer
Devices Personnel
 HSMN NewsFeed - 22 Apr 2020
Novartis Kymriah(R) receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma
Biopharmaceuticals Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 13 Apr 2020
Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Apr 2020
U.S. FDA Grants CytoSorb(R) Emergency Use Authorization for Use in Patients with COVID-19 Infection
Devices FDA
 HSMN NewsFeed - 31 Mar 2020
CytoSorb(R) Receives Marketing Approval in Mexico with Commercialization to Commence with Partner Fresenius Medical Care
Devices Regulatory
 HSMN NewsFeed - 4 Mar 2020
Alopexx Oncology Announces Licensing Agreement with Beijing Shenogen Pharma Group for Development and Commercialization of Novel Immunocytokine for the Treatment of B-Cell Lymphomas in China/Asia
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Jan 2020
CytoSorb(R) is Approved and Available for the Removal of Ticagrelor, a Leading Anti-Platelet Drug, During Cardiopulmonary Bypass in the E.U.
Devices Regulatory Product Launch
 HSMN NewsFeed - 8 Jan 2020
Former Celgene Chairman and CEO Mark J. Alles Joins Antengene Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jan 2020
Antengene Corporation Appoints Former Celgene China GM John Chin as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Dec 2019
FDA clears Cochlear's innovative new Osia(R) 2 hearing implant system
Devices FDA
 HSMN NewsFeed - 7 Nov 2019
CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement for Octreotide Long Acting Injectable (LAI) Microsphere for Neuroendocrine Cancers and Acromegaly
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 1 Nov 2019
CytoSorbents Enrolls First Patient in TISORB Trial and Opens Operating Subsidiary in the United Kingdom
Devices
 HSMN NewsFeed - 19 Sep 2019
CASI Pharmaceuticals Announces the Promotion of Larry Zhang to President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2019
Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to Prepare NDA Filing in Europe
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Aug 2019
CASI Pharmaceuticals Announces Launch of EVOMELA(R) (melphalan for injection) in China
Biopharmaceuticals Oncology Product Launch
 HSMN NewsFeed - 17 Jun 2019
CASI Pharmaceuticals Acquires Worldwide Rights To Commercialize anti-CD19 T-cell Therapy
Biopharmaceuticals Oncology Licensing Acquisitions
 HSMN NewsFeed - 20 May 2019
Rinri Therapeutics Secures £1.4 Million Seed Funding to Advance Its Novel Regenerative Cell Therapy to Treat Sensorineural Hearing Loss
Regenerative Medicine Venture Capital Personnel
 HSMN NewsFeed - 25 Mar 2019
Israel Approves CytoSorb Registration, CytoSorbents Announces Gad Medical as Distributor
Devices Regulatory Distribution
 HSMN NewsFeed - 15 Oct 2018
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301 for the Treatment of Cutaneous T-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Oct 2018
Trovagene Announces Exclusive License Agreement with MIT for Combination Therapy of Anti-Androgens and Polo-like Kinase Inhibitors in Prostate Cancer
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Aug 2018
Trovagene Announces European Commission Grants Orphan Drug Designation to Onvansertib (PCM-075) for Treatment of Acute Myeloid Leukemia in Europe
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Aug 2018
Daiichi Sankyo Presents First Snapshot Analyses from Global ETNA-AF Programme of Oral, Once-daily LIXIANA(R) (edoxaban) in Patients with Nonvalvular Atrial Fibrillation in Routine Clinical Practice
Biopharmaceuticals
 HSMN NewsFeed - 27 Aug 2018
AbbVie Announces IMBRUVICA(R) (ibrutinib) Plus Rituximab Approval by U.S. FDA as First Chemotherapy-Free Combination Treatment in Adults with Waldenström's Macroglobulinemia, a Rare Type of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Aug 2018
Siklos(R), the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now available in retail pharmacies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 9 Jul 2018
Results of Phase III (PIX306) Trial Evaluating Progression-Free Survival of PIXUVRI(R) (pixantrone) Combined with Rituximab in Patients with Aggressive B-cell Non-Hodgkin Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2018
IMBRUVICA(R) (ibrutinib) Supplemental New Drug Application Accepted for Review by U.S. FDA with Potential to Broaden Treatment Use as a Combination Treatment Option with Rituximab in Waldenström's Macroglobulinemia (WM), A Rare Form of Blood Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Jun 2018
Nordic Nanovector Appoints Eduardo Bravo as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 May 2018
FDA expedites review of Novartis drug Promacta(R) for first-line severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2018
Biopharm Startup TFF Pharmaceuticals Raises $14M for Breakthrough Dry Powder Inhalation Platform
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Mar 2018
Abbott's MitraClip Therapy Receives National Reimbursement in Japan to Treat Patients with Mitral Regurgitation
Devices Cardiology Reimbursement
 HSMN NewsFeed - 4 Jan 2018
Novartis drug Promacta(R) receives FDA Breakthrough Therapy designation for first-line use in severe aplastic anemia (SAA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Nov 2017
Amgen Receives Positive CHMP Opinion To Expand Use Of Nplate(R) (romiplostim) In Pediatric Patients With Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Nov 2017
Abbott's MitraClip Approved as First Transcatheter Mitral Valve Repair Device in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 20 Sep 2017
Trovagene Strengthens Board of Directors with Appointment of Oncology Development Veteran Dr. Athena Countouriotis
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Aug 2017
Gamida Cell Announces First Patient Transplanted in Phase 1/2 Study of CordIn for Severe Aplastic Anemia and Hypoplastic MDS
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2017
CHMP Issues a Positive Opinion for Daiichi Sankyo's Once-Daily LIXIANA(R) (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology Regulatory
 HSMN NewsFeed - 10 May 2017
Savara Announces Expedited U.S. Molgradex Development Strategy
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Apr 2017
Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
Devices Interventional Drug Delivery
 HSMN NewsFeed - 24 Apr 2017
Mustang Bio Announces Appointment of Manuel Litchman, M.D., as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Mar 2017
Forty Seven Inc. Announces Mark McCamish, M.D., Ph.D., to Join as CEO on May 1st
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 Dec 2016
CytoSorb(R) Attains Permanent, Dedicated Reimbursement Code in Core Market of Germany
Devices Reimbursement
 HSMN NewsFeed - 28 Nov 2016
Toshiba Medical’s Fully Integrated Model-Based Iterative CT Reconstruction Receives FDA Clearance
Devices Radiology FDA Product Launch
 HSMN NewsFeed - 22 Nov 2016
First Successful Treatment of Dengue Fever and Dengue Shock Syndrome Using CytoSorb(R)
Devices
 HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 6 Oct 2016
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Aug 2016
Telesta Therapeutics Announces Execution of a Binding Purchase Agreement from ProMetic Life Sciences Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Jul 2016
Genentech Provides Update on Phase III Study of Gazyva(R) in People With Previously Untreated Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Mar 2016
ProNAi Therapeutics Granted Orphan Drug Designation for PNT2258 for the Treatment of Diffuse Large B-Cell Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Feb 2016
Telesta Therapeutics Receives Complete Response Letter from FDA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Dec 2015
Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Dec 2015
Teva Pharmaceuticals and Eagle Pharmaceuticals Announce FDA Approval of BENDEKA(TM) (bendamustine hydrochloride) Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2015
Spectrum Pharmaceuticals Divests Rights to ZEVALIN(R) (ibritumomab tiuxetan) in Japan and Select Other Ex-US Countries to Mundipharma
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2015
Abbott Announces Positive Clinical Results of Absorb(TM), the Naturally Dissolving Heart Stent
Devices Interventional Cardiology
 HSMN NewsFeed - 5 Aug 2015
Hetero Announces the Launch of Biosimilar Rituximab (MABALL(TM)) in India
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 12 Jun 2015
FDA Approves Promacta(R) for New Pediatric Chronic Immune Thrombocytopenia (cITP) Indication
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 May 2015
Abbott Announces CE Mark for New Advancement of Absorb Stent System for People with Heart Disease
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 4 Feb 2015
Genentech’s Phase III Study of Gazyva(R) Showed Significant Benefit in Refractory Indolent Non-Hodgkin’s Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Nov 2014
Bioniche Life Sciences Inc. Rebrands as Telesta Therapeutics Inc.
Biopharmaceuticals
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Sep 2014
CTI BioPharma And Servier Announce Exclusive License And Collaboration Agreement To Develop And Commercialize PIXUVRI(R)
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 27 Aug 2014
Ligand Partner GlaxoSmithKline Receives U.S. FDA Approval for Promacta(R)/Revolade(TM) For Use in Patients with Severe Aplastic Anemia
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Mar 2014
Daiichi Sankyo Initiates Phase 3 ENSURE-AF Study, Investigating Once-Daily Edoxaban in Patients with Atrial Fibrillation Undergoing Cardioversion
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 14 Mar 2014
GSK and Theravance Announce Positive Results From Studies Comparing ANORO(TM) ELLIPTA(TM) With SERETIDE(R) DISKUS(R) and ADVAIR(R) DISKUS(R) in Patients With COPD
Biopharmaceuticals
 HSMN NewsFeed - 6 Feb 2014
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Beleodaq(TM) (belinostat) for Injection, a novel pan-HDAC inhibitor
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 18 Nov 2013
Actinium Pharmaceuticals Announces Plans For Iomab(TM)-B Phase 3 Pivotal Trial Following Meeting With FDA
Biopharmaceuticals
 HSMN NewsFeed - 1 Nov 2013
FDA Approves Gazyva (Obinutuzumab) for People With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Oct 2013
Given Imaging Announces Data Confirming PillCam(R) SB Can Improve Management and Outcomes in Patients With Crohn's Disease
Devices Gastroenterology
 HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Aug 2013
Epratuzumab and Rituximab Produce High Rate and Durable Progression-Free Survival in Previously Untreated Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2013
Abbott Announces Approval of Next-Generation XIENCE Xpedition(TM) Drug Eluting Stent System in Japan
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 3 Jul 2013
FDA Grants Genentech’s Obinutuzumab (GA101) Priority Review for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Apr 2013
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Mar 2013
Spectrum Pharmaceuticals Gains Rights to Pivotal-Stage Captisol-Enabled(R) Melphalan
Biopharmaceuticals Licensing
 HSMN NewsFeed - 11 Jan 2013
Spectrum Pharmaceuticals Announces Promotion of Joseph Turgeon to Senior Vice President and Chief Commercial Officer as Company Builds on Recent Commercial Reorganization to Advance Growth and Market Penetration over the Next Five Years
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jan 2013
Thoratec Announces FDA Approval To Commence REVIVE-IT Study Utilizing HeartMate II
Devices Cardiology FDA
 HSMN NewsFeed - 21 Dec 2012
Spectrum Pharmaceuticals Announces Achievement of Primary Endpoint in Belinostat Registrational Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Dec 2012
First U.S. Patient Treated Following FDA Approval of Cook Medical’s First-of-its-Kind Zilver(R) PTX(R) Drug-Eluting Peripheral Stent
Devices Interventional
 HSMN NewsFeed - 31 Oct 2012
Takeda and Millennium Announce European Conditional Marketing Authorization for ADCETRIS(R) (Brentuximab Vedotin)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Sep 2012
Abbott Announces International Launch of the Absorb(TM) Bioresorbable Vascular Scaffold
Devices Interventional Cardiology
 HSMN NewsFeed - 11 Sep 2012
Cell Therapeutics Announces European Launch Of Pixuvri(R) For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2012
Talon Therapeutics Appoints Head of Commercial Operations and Planning
Biopharmaceuticals Drug Delivery Oncology Personnel
 HSMN NewsFeed - 5 Apr 2012
Spectrum Pharmaceuticals to Acquire Allos Therapeutics: Acquisition Expected to Be Accretive on a Cash Basis in Q4 of 2012
Biopharmaceuticals Mergers & Acquisiitons
 HSMN NewsFeed - 30 Jan 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2012
Amgen to Acquire Micromet
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 20 Jan 2012
Allos Therapeutics Receives Negative Opinion from the CHMP on FOLOTYN
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Oct 2011
Given Imaging Announces New Studies Validate Use of PillCam SB(R) to Detect and Monitor Crohn's Disease
Devices Gastroenterology
 HSMN NewsFeed - 18 Oct 2011
Halozyme Announces Positive Results from Roche's Subcutaneous Herceptin Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2011
Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Aug 2011
Boehringer Ingelheim to Launch RE-ALIGN Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 17 Aug 2011
Allos Therapeutics Initiates Phase 3 Registration Trial of FOLOTYN(R) in Newly Diagnosed Patients with Peripheral T-Cell Lymphoma Following Treatment with a CHOP-based Regimen
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Apr 2011
FDA Approves Rituxan Plus a Steroid for Use in Severe Forms of Vasculitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2011
FDA Accepts for Review Spectrum Pharmaceuticals’ ZEVALIN(R) Submission for the Removal of the Bioscan
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Mar 2011
Lantheus Medical Imaging Receives Special Protocol Assessment Approval from FDA for Phase 3 Trial of Flurpiridaz F-18 for the Diagnosis of Coronary Artery Disease
Biopharmaceuticals Radiology Cardiology FDA
 HSMN NewsFeed - 10 Mar 2011
Given Imaging Receives FDA Clearance for Expanded PillCam(R) SB Indications
Devices Gastroenterology FDA
 HSMN NewsFeed - 24 Feb 2011
Spectrum Pharmaceuticals Appoints Steven M. Fruchtman, MD, an Industry Veteran, as Vice President of Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Feb 2011
Gilead Sciences to Acquire Calistoga Pharmaceuticals for $375 Million
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 16 Feb 2011
Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera(R) (rituximab)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2010
Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2010
European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Oct 2010
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology Neurology FDA
 HSMN NewsFeed - 14 Sep 2010
Cell Therapeutics to Appeal FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 May 2010
New Studies Presented at Digestive Disease Week Highlight the Value of PillCam(R) Capsule Endoscopy
Devices Gastroenterology
 HSMN NewsFeed - 9 Apr 2010
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Mar 2010
Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jan 2010
Lantheus Medical Imaging, Inc. Launches ABLAVAR (Gadofosveset Trisodium), a New Diagnostic Magnetic Resonance Angiography Agent
Biopharmaceuticals Radiology
 HSMN NewsFeed - 15 Jan 2010
St. Jude Medical Announces Sponsorship of SCD-HeFT 10-Year Follow-Up Study
Devices Cardiology
 HSMN NewsFeed - 6 Jan 2010
Acton Pharmaceuticals, Inc. Announces Completion of $15 Million Series A Financing with Sequoia Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Dec 2009
European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2009
Ligand Announces Positive Regulatory Opinion in Europe for Revolade for Chronic Immune Thrombocytopenic Purpura
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Dec 2009
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
Phase III Data Showed Rituxan Plus Chemotherapy Improved Survival in Patients With Most Common Form of Adult Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2009
Celgene to Acquire Gloucester Pharmaceuticals
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 23 Nov 2009
BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries
Devices Interventional Cardiology Regulatory
 HSMN NewsFeed - 5 Nov 2009
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2009
ZEVALIN(R) Receives Positive Reimbursement Ruling Using Average Sales Price (ASP) Methodology
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 29 Sep 2009
Cell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Sep 2009
Cook Medical's Advanced NavAlign Delivery System for IVC Filters Adds Procedural Speed, Control and Accuracy
Devices
 HSMN NewsFeed - 17 Sep 2009
Phase III Study Showed Patients Lived Longer Without Low-Grade Lymphoma Progressing When Rituxan Was Used First-Line for Maintenance
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Aug 2009
Genmab Announces Positive Top-Line Results for Arzerra(TM) in Front Line NHL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jul 2009
Cephalon Appoints Craig C. Phillips as Vice President and General Manager of Oncology Business Unit
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 20 Jul 2009
ChemGenex Appoints Mr. Thomas DeZao as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Jun 2009
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Jun 2009
BARI 2D Study Presented at American Diabetes Association Scientific Sessions Underscores Utility of SPECT Myocardial Perfusion Imaging in Identifying Cardiovascular Risk and Evaluating Treatment Outcomes for Patients with Type 2 Diabetes
Biopharmaceuticals Radiology Cardiology
 HSMN NewsFeed - 9 Jun 2009
Masimo Debuts New Rad-8(R) Pulse Oximeter to Largest Gathering of Sleep Specialists From Around the World at SLEEP 2009
Devices Monitoring
 HSMN NewsFeed - 5 Jun 2009
Single Dose Palonosetron Prevents Emesis Induced by Chemotherapy in Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 May 2009
AZOR(R) Receives FDA Approval as First-Line Treatment for High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2009
New Data Shows Blood Pressure Reduction Therapy With BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2009
New Data Shows AZOR(R) (Amlodipine and Olmesartan Medoxomil) Significantly Improves 24-Hour Ambulatory Blood Pressure
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 5 May 2009
Pixantrone Now Available in Europe on a Named-Patient Basis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Apr 2009
Immunomedics Reports Results That Could Expand Use of Milatuzumab in Cancer Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Mar 2009
Boehringer Ingelheim Plans to Launch U.S. Registry to Assess the State of Anticoagulation Therapy for Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 23 Mar 2009
U.S. FDA Approves New THERAKOS(TM) CELLEX(TM) Photopheresis System
Devices Oncology FDA
 HSMN NewsFeed - 20 Mar 2009
Final Patient Completes Treatment In Boehringer Ingelheim's RE-LY(R) Study, The Largest Atrial Fibrillation Outcomes Trial To Date
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 16 Mar 2009
Spectrum Pharmaceuticals Acquires 100% of ZEVALIN, an FDA-Approved, Proprietary, Biological Drug for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 11 Mar 2009
Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Feb 2009
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2009
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Jan 2009
Immunomedics Reports Properties and Structure-Function Relationships of Veltuzumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2009
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Dec 2008
FDA Approves Genzyme's Mozobil
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2008
Rituxan in Combination with Chemotherapy Improves Progression-Free Survival in Difficult-to-Treat Form of Blood Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Nov 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Cephalon Receives FDA Approval for TREANDA to Treat Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2008
Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jul 2008
Genmab and GlaxoSmithKline Announce Positive Top-Line Results in Ofatumumab Chronic Lymphocytic Leukemia Pivotal Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jul 2008
Immunomedics Announces Worldwide License and Collaboration Agreement With Nycomed for Veltuzumab for Non-Cancer Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jun 2008
Biovest Reports Blinded Results for Phase 3 Study Evaluating Anti-Cancer Vaccine, BiovaxID(R), which Shows 100% Difference in Disease-Free Survival at 36 Months in the Comparative Arms
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2008
AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 May 2008
Favrille Announces Results from Phase 3 Registration Trial of Specifid in Patients with Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 May 2008
Sepracor and Arrow Sign Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA(R) Franchises
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 May 2008
Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX(R)/Ipratropium Inhalation Solution Combination
Biopharmaceuticals Licensing
 HSMN NewsFeed - 29 Apr 2008
Genentech and Biogen Idec Announce Top-Line Results from Phase II/III Clinical Study of Rituxan in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 24 Apr 2008
Veteran Drug Industry Executive to Become President of CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Apr 2008
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2008
Dynavax and Merck & Co., Inc. Update Status of Clinical Hold of Investigational Vaccine HEPLISAV(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 Apr 2008
SPP100 (Tekturna/Rasilez) Reduces Left Ventricular Hypertrophy
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 31 Mar 2008
Phase III Data Showed Taranabant, Merck's Investigational Medicine to Treat Obesity, Led to Statistically Significant Weight Loss
Biopharmaceuticals
 HSMN NewsFeed - 28 Mar 2008
New York-Presbyterian/Weill Cornell is First New York Medical Center to Offer Tantalus Clinical Trial to Diabetes Patients
Devices Endocrinology
 HSMN NewsFeed - 25 Mar 2008
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2008
Immunomedics Develops New Immunoconjugates for Targeted Chemotherapy of Pancreatic and Other Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2008
Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Mar 2008
Cook Medical Receives FDA 510(k) Clearance for Celect(TM) Vena Cava Filter and Gunther Tulip(TM) Vena Cava Filter Retrieval Set
Devices FDA
 HSMN NewsFeed - 18 Mar 2008
Immunomedics' Milatuzumab Receives FDA Orphan Drug Designation for Therapy of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Mar 2008
Dynavax and Merck & Co., Inc. Report Clinical Hold of Investigational Vaccine HEPLISAV
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Mar 2008
FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2008
Cardima Announces Appointment of Dr. Sanjeev Saksena to Scientific Advisory Board as FDA Regulatory Consultant
Devices Cardiology Personnel
 HSMN NewsFeed - 20 Feb 2008
Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2008
FDA Accepts TREANDA(R) New Drug Application for the Treatment of Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2008
FDA Approves ASMANEX (R) TWISTHALER(R) (Mometasone Furoate Inhalation Powder) for the Once Daily Maintenance Treatment of Asthma in Children Ages 4-11
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jan 2008
Allos Therapeutics Appoints Bruce K. Bennett as Vice President, Manufacturing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Jan 2008
Genentech and Biogen Idec Announce Positive Results from a Phase III Trial of Rituxan in Patients with Rheumatoid Arthritis Who Inadequately Responded to Methotrexate
Biopharmaceuticals
 HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jan 2008
ALVESCO(R) Gains FDA Approval for the U.S. Market
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 Dec 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 20 Dec 2007
GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2007
Once-Daily Exjade(R) Shown to Remove Toxic Iron From the Heart and Liver, According to Data Presented at ASH
Biopharmaceuticals
 HSMN NewsFeed - 10 Dec 2007
Epratuzmab Plus Rituximab Produce Durable Complete Responses in Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Dec 2007
Favrille to Report New Data on FavId (Now Specifid) at American Society of Hematology Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Nov 2007
New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Nov 2007
Dynavax and Merck & Co., Inc. Announce Partnership to Develop HEPLISAV(TM), an Investigational Hepatitis B Vaccine Currently in Phase 3
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2007
Cephalon Announces Positive Results from Its Pivotal Study of TREANDA in Patients with Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Oct 2007
Biovest Announces Strategy for Seeking Early Approval of Its Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2007
Celera and Collaborators Identify a Five-Gene Genetic Risk Score(TM) That Predicts Risk of Coronary Heart Disease
Diagnostics Cardiology
 HSMN NewsFeed - 27 Sep 2007
AZOR(TM) Receives FDA Approval for Treatment of High Blood Pressure
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 Sep 2007
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2007
Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
Biopharmaceuticals
 HSMN NewsFeed - 12 Sep 2007
Micromet Appoints Mark Reisenauer as Senior Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Aug 2007
FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology
 HSMN NewsFeed - 19 Jul 2007
Genzyme Announces Phase 3 Trial of Mozobil in non-Hodgkin's Lymphoma Meets Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2007
Coley Pharmaceutical Group Grants Dynavax License for Commercialization of HEPLISAV(TM)
Biopharmaceuticals Licensing
 HSMN NewsFeed - 28 Jun 2007
Cephalon Announces Plans for New NDA Filing for TREANDA(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jun 2007
NCCN Updates Non-Hodgkin's Lymphoma Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2007
Genmab Announces Development Plans for Ofatumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2007
Latest Data Show MabThera(R) Provides Significant and Sustained Relief From Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2007
Favrille Announces Data From Phase 2 Clinical Trial of FavId for Indolent B-Cell Non-Hodgkin's Lymphoma in Europe
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
Biovest to File for Accelerated Conditional Approval of BiovaxID
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2007
8-Year Long-Term Data Demonstrate Prolonged Overall Survival and Length of Disease Remission With Bexxar(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Cytokinetics Announces the Presentation of Clinical Trials Data at the 2007 Annual Meeting of the American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Phase 2 Clinical Results of Ganite(R) Plus Standard Therapy in Patients with Relapsed/Refractory Lymphoma Presented at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Favrille Reports Status of Phase 2 Clinical Trial of FavId With Maintenance Rituxan for Indolent B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Data Show Improved Response Rate When Zevalin Plus Rituximab Follows Short Course First-Line Treatment in Patients with Follicular Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin's Lymphoma Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2007
Genitope Corporation Initiates Clinical Trial to Evaluate Use of MyVax(R) Personalized Immunotherapy Following Treatment With Rituximab and Chemotherapy for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 May 2007
Favrille Appoints Richard Ghalie, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2007
Rituxan(R) Phase II Data in Patients with Relapsing-Remitting Multiple Sclerosis Presented at the American Academy of Neurology
Biopharmaceuticals Neurology
 HSMN NewsFeed - 30 Apr 2007
Dr Reddy's launches Reditux(TM) - Monoclonal Antibody Treatment for Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2007
Allos Therapeutics' PDX Granted Orphan Medicinal Product Designation by the European Commission
Biopharmacetuicals Oncology Regulatory
 HSMN NewsFeed - 12 Apr 2007
GSK Initiates REPEAT Dosing Study of Its Novel Oral Platelet Growth Factor, PROMACTA(R), in ITP
Biopharmaceuticals
 HSMN NewsFeed - 11 Apr 2007
BROVANA(TM) Inhalation Solution Now Available by Prescription for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals
 HSMN NewsFeed - 26 Mar 2007
Enzastaurin Granted Orphan Drug Status for Treatment of Diffuse Large B-Cell Lymphoma (DLBCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Mar 2007
Philips Speeds Care and Improves the Patient Experience Throughout Cardiac Care Cycles
Devices Cardiology Radiology
 HSMN NewsFeed - 20 Mar 2007
DOR BioPharma Forms orBec(R) Medical Advisory Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Mar 2007
Anthera Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board for Respiratory and Acute Care Programs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Feb 2007
Dynavax Reports Interim, One-Year Data From Ragweed Allergy Trial at AAAAI
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2007
Favrille Announces Agreement With Berlex, Inc. Regarding Use of FavId(R) in Combination With Leukine(R) (sargramostim) in B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Feb 2007
Favrille Announces Long-Term Follow-Up Data From Phase 2 Clinical Trial of FavId Following Autologous Stem Cell Transplantation for B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jan 2007
Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2007
Cephalon Comments on Study of its Leukemia Treatment Led by National Cancer Institute Cooperative Group
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jan 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Dec 2006
Dynavax Initiates Pivotal Phase 3 Trial for HEPLISAV(TM), Hepatitis B Vaccine
Biopharmaceuticals
 HSMN NewsFeed - 19 Dec 2006
GlaxoSmithKline and Genmab Enter Global Agreement For HuMax-CD20
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Dec 2006
CuraGen and TopoTarget Announce Expansion of Belinostat (PXD101) Clinical Trial in Cutaneous T-cell Lymphoma (CTCL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
VELCADE(R) (Bortezomib) for Injection Demonstrates Substantial Activity Across Range of Lymphomas
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
Trial Data Showed Promacta(TM) (Eltrombopag) Decreased Bleeding Episodes and Improved Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura
Biopharmaceuticals
 HSMN NewsFeed - 11 Dec 2006
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Dec 2006
FDA Approves VELCADE(R) (Bortezomib) for Injection for Aggressive Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2006
49 Abstracts Evaluating Revlimid(R) To Be Presented at The 48th American Society of Hematology Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Publications Feature VELCADE(R) (Bortezomib) for Injection Strength In Hematological Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Study Showed Epratuzumab in Combination with Rituximab and Chemotherapy is Safe, Tolerable, and Active in Aggressive Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2006
Cytokinetics and GlaxoSmithKline Amend Collaboration and License Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 13 Nov 2006
Epratuzumab and Rituximab Have Different Modes of Action
Biopharmaceuticals
 HSMN NewsFeed - 13 Nov 2006
Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Oct 2006
Berlex Oncology Evaluating Combination Therapy for Common Form of Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Oct 2006
Millennium and Ortho Biotech Enter into U.S. Co-Promotion Agreement for VELCADE(R)(bortezomib) for Injection
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2006
BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference
Biopharmaceuticals
 HSMN NewsFeed - 22 Oct 2006
Study Results Found Low-Dose Orlistat (60 mg) Demonstrates Significant Reduction in LDL Cholesterol While Providing Weight Loss for Up to Two Years
Biopharmaceuticals
 HSMN NewsFeed - 12 Oct 2006
Favrille Appoints Former Eli Lilly Executive Michael Eagle Chairman of the Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2006
Micromet, Inc. Expands Management and Appoints Christopher P. Schnittker as Senior Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Oct 2006
Diatos Strengthens Management Team with the Appointment of New Chief Medical Officer and New Chief Sales & Marketing Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Oct 2006
FDA Approves Sepracor's BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution for Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Oct 2006
Journal of Clinical Oncology Publishes Final Study Results of VELCADE(R) (Bortezomib) for Injection in Relapsed Mantle Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Oct 2006
Schering AG and Biogen Idec Announce Start of the ZEAL Phase III Clinical Trial With Anti-Cancer Drug Zevalin(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Oct 2006
Updated REVLIMID(R) (lenalidomide) Clinical Results Presented at the 3rd International Conference on Innovative Therapies for Lymphoid Malignancies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2006
FDA Approves Two New Indications for Rituxan(R) in Patients With Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Sep 2006
Millennium Agrees to Acquire AnorMED, Adding Phase III Oncology Product with Planned Near Term Launch Date
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 13 Sep 2006
Impulse Dynamics Announces New Data Regarding Its Optimizer System Utilizing Cardiac Contractility Modulation (CCM) Technology
Devices Cardiology
 HSMN NewsFeed - 10 Jul 2006
AnorMED completes enrollment in Phase III trial for MOZOBIL in stem cell transplant in multiple myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jul 2006
Favrille Publishes Data From Phase 2 Clinical Trial Demonstrating Biologic Activity of Lead Product Candidate FavId in Indolent Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jun 2006
Analysis of Phase III Study Showed Rituxan(R) Plus Methotrexate Reduced Joint Damage in Rheumatoid Arthritis Patients Who Respond Inadequately to TNF Antagonist Therapies
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
FDA Gives Permission to Use Very Sensitive Molecular Evidence of Cancer in BiovaxID Pivotal Phase 3 Clinical Trial
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 May 2006
Bioenvision and Mayne Pharma Announce Marketing and Distribution Agreement for Evoltra(R)
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 8 May 2006
Hana Biosciences Completes Licensing of Three Targeted Cancer Drug Candidates from Inex Pharmaceuticals
Biopharmaceuticals Oncology Licensing
Return to NewsFeed  

 Additional items found! 199

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 199 additional stories matching:
NHL
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!